左西孟旦对经皮冠状动脉介入术后患者心脏储备功能及无复流心力衰竭风险的影响  

Effect of Levosimendan on Cardiac Reserve Function and Risk of No-reflow Heart Failure in Patients After Percutaneous Coronary Intervention

作　　者：胡雨平 叶民珠 HU Yu-ping;YE Min-zhu(Department of Cardiovascular Medicine,Ganxian District People's Hospital,Ganzhou 341100,Jiangxi,China)

机构地区：[1]赣县区人民医院心血管内科,江西赣州341100

出　　处：《医学信息》2022年第23期125-128,共4页Journal of Medical Information

摘　　要：目的研究左西孟旦对经皮冠状动脉介入术(PCI)后患者心脏储备功能及无复流心力衰竭风险的影响。方法选取2019年8月-2021年7月于赣县区人民医院行PCI治疗的68例患者,按照随机数字表法分为对照组与观察组,各34例。对照组给予常规治疗,观察组则在对照组基础上给予左西孟旦治疗,比较两组临床疗效、心脏储备功能[左心室射血分数(LVEF)、左室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)]、炎症因子[超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、细胞间黏附分子-1(ICAM-1)]、肾功能指标[血肌酐(Scr)、血尿素氮(BUN)]、主要不良心血管事件(MACE)发生率。结果观察组治疗总有效率为94.12%,高于对照组的82.35%(P<0.05);观察组LVEF高于对照组,LVEDD、LVESD低于对照组(P<0.05);观察组hs-CRP、TNF-α、ICAM-1水平低于对照组(P<0.05);观察组Scr、BUN水平低于对照组(P<0.05);观察组MACE发生率为5.88%,低于对照组的20.59%(P<0.05)。结论左西孟旦可提高PCI患者临床疗效,改善其心脏储备功能,下调炎性指标,同时缓解肾功能损害,降低无复流心力衰竭等不良心血管事件的发生风险。Objective To study the effect of levosimendan on cardiac reserve function and risk of no-reflow heart failure in patients after percutaneous coronary intervention(PCI).Methods A total of 68 patients who underwent PCI in Ganxian District People's Hospital from August 2019 to July 2021 were selected and divided into control group and observation group according to random number table method,with 34 cases in each group.The control group was given routine treatment,while the observation group was treated with levosimendan on the basis of the control group.The clinical efficacy,cardiac reserve function[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)],inflammatory factors[high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α),intercellular adhesion molecule-1(ICAM-1)],renal function indexes[serum creatinine(Scr),blood urea nitrogen(BUN)],incidence of major adverse cardiovascular(MACE)were compared between the two groups.Results The total effective rate of the observation group was 94.12%,which was higher than 82.35%of the control group(P<0.05).LVEF in the observation group was higher than that in the control group,LVEDD and LVESD were lower than those in the control group(P<0.05).The levels of hs-CRP,TNF-αand ICAM-1 in the observation group were lower than those in the control group(P<0.05).The levels of Scr and BUN in the observation group were lower than those in the control group(P<0.05).The incidence of MACE in observation group was 5.88%,which was lower than 20.59%in control group(P<0.05).Conclusion Levosimendan can improve the clinical efficacy of PCI patients,improve their cardiac reserve function,down-regulate inflammatory indicators,alleviate renal function damage,and reduce the risk of adverse cardiovascular events such as no-reflow heart failure.

关 键 词：经皮冠状动脉介入术 左西孟旦 心脏储备功能 无复流心力衰竭 肾功能 

分 类 号：R541[医药卫生—心血管疾病]